Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Nanotechnology enables Personalized Medicine
share announcement

Nanotechnology enables Personalized Medicine

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2902

Special Issue Editors

Dr. Sebastian Schwaminger

E-Mail Website
Guest Editor
Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria
Interests: drug delivery; nanoparticles; nanotechnology; magnetic particles; magnetic separation
Special Issues, Collections and Topics in MDPI journals
Dr. Ruth Prassl

E-Mail Website
Guest Editor
Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Biophysics/Nanomedicine, Medical University of Graz, Graz, Austria
Interests: nanomedicine; drug delivery; biomaterials; liposomes; lipoprotein mimetics; biophysical characterization; structural biology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Andreas Zimmer

E-Mail Website1 Website2
Guest Editor
Department for Pharmaceutical Technology and Biopharmacy, University of Graz, Graz, Austria
Interests: drug delivery; drug targeting; nanoparticles; lipids; lipid coating
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomaterials have changed the fields of medicine and biotechnology in recent years. Nanotechnology has advanced the fields of regenerative medicine and biomedical applications as well as drug delivery and nanotherapy. Novel materials and particle shapes are introduced to medical applications every day. In addition to novel materials, the new developments are also driven by the newest developments in the pharmaceutical industry and the demand of pharmaceuticals. A special focus of this issue therefore also lies on pharmaceutical nanotechnology and on lipid nanoparticle gene delivery systems. We want to invite contributions addressing the field of Nanotechnology for Medicine and Biotechnology (BioNanoMed) and especially address all participants of the BioNanoMed Conference Graz 2023. Contributions should address the following fields:

  • Nanomaterials for Biomedical Applications & Regenerative Medicine
  • Drug Delivery and Nanotherapy
  • Nanotechnology for Imaging, Sensing and Diagnostics
  • Biophysical Nanotechnology and Single-Molecule Technologies
  • Pharmaceutical Nanotechnology and Drug Design
  • Lipid Nanoparticle Gene Delivery Systems and Vaccines

Dr. Sebastian Schwaminger
Dr. Ruth Prassl
Prof. Dr. Andreas Zimmer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

30 pages, 7376 KiB  
Article
Development and Characterization of Cationic Nanostructured Lipid Carriers as Drug Delivery Systems for miRNA-27a
by Amina Tucak-Smajić, Ivana Ruseska, Ilse Letofsky-Papst, Edina Vranić and Andreas Zimmer
Pharmaceuticals 2023, 16(7), 1007; https://doi.org/10.3390/ph16071007 - 14 Jul 2023
Cited by 3 | Viewed by 2383
Abstract
Although miRNA-27a has been identified as a promising candidate for miRNA mimic therapy of obesity, its application is limited due to enzymatic degradation and low membrane permeation. To overcome these problems, we developed cationic nanostructured lipid carriers (cNLCs) using high-pressure homogenization and used [...] Read more.
Although miRNA-27a has been identified as a promising candidate for miRNA mimic therapy of obesity, its application is limited due to enzymatic degradation and low membrane permeation. To overcome these problems, we developed cationic nanostructured lipid carriers (cNLCs) using high-pressure homogenization and used them as non-viral carriers for the anti-adipogenic miRNA-27a. Cargo-free octadecylamine-containing NLCs and miRNA/cNLC complexes were characterized regarding particle size, size distributions, zeta potential, pH values, particle topography and morphology, and entrapment efficacy. Furthermore, the cytotoxicity and cellular uptake of the miRNA/cNLC complex in the 3T3-L1 cell line were investigated. The investigation of the biological effect of miRNA-27a on adipocyte development and an estimation of the accumulated Oil-Red-O (ORO) dye in lipid droplets in mature adipocytes were assessed with light microscopy and absorbance measurements. The obtained data show that cNLCs represent a suitable DDS for miRNAs, as miRNA/cNLC particles are rapidly formed through non-covalent complexation due to electrostatic interactions between both components. The miRNA-27a/cNLC complex induced an anti-adipogenic effect on miRNA-27a by reducing lipid droplet accumulation in mature adipocytes, indicating that this approach might be used as a new therapeutic strategy for miRNA mimic replacement therapies in the prevention or treatment of obesity and obesity-related disorders. Full article
(This article belongs to the Special Issue Nanotechnology enables Personalized Medicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop